Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4821722 | 1.00 | SIGMAR1 (0.59) | SIGMAR1MC4R | |
| SCHEMBL7383165 | 0.86 | SIGMAR1 (0.60) | SIGMAR1MC4R | |
| SCHEMBL10842850 | 0.85 | SIGMAR1 (0.56) | SIGMAR1MC4R | |
| SCHEMBL24326317 | 0.84 | SIGMAR1 (0.67) | SIGMAR1MC4R | |
| SCHEMBL3436828 | 0.84 | SIGMAR1 (0.67) | SIGMAR1MC4R | |
| SCHEMBL3343632 | 0.83 | SIGMAR1 (0.58) | SIGMAR1 | |
| SCHEMBL15709182 | 0.81 | SIGMAR1 (0.56) | SIGMAR1 | |
| SCHEMBL25154734 | 0.81 | SIGMAR1 (0.59) | SIGMAR1MC4R | |
| SCHEMBL25154270 | 0.81 | SIGMAR1 (0.59) | SIGMAR1MC4R | |
| SCHEMBL9594834 | 0.80 | DRD4 (0.50) | SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7365077-B2 | Piperazine bis-amide derivatives and their use as antagonists of the orexin receptor | SMITHKLINE BEECHAM P.L.C. (GB) | 2008-04-29 | — | — | US | disclosed |
| US-20060252769-A1 | Piperazine bis-amide derivatives and their use as antagonists of the orexin receptor | SMTIHKLINE BEECHAM P.L.C. (GB) | 2006-11-09 | — | — | US | disclosed |
| EP-1441729-A1 | PIPERAZINE BIS-AMIDE DERIVATIVES AND THEIR USE AS ANTAGONISTS OF THE OREXIN RECEPTOR | SMITHKLINE BEECHAM PLC (GB) | 2004-08-04 | — | — | EP | disclosed |
| WO-2003041711-A1 | PIPERAZINE BIS-AMIDE DERIVATIVES AND THEIR USE AS ANTAGONISTS OF THE OREXIN RECEPTOR | SMITHKLINE BEECHAM P.L.C. (GB) | 2003-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060252769-A1 | Piperazine bis-amide derivatives and their use as antagonists of the orexin receptor | HCRTR2, HCRTR1, NPSR1 | SIGMAR1 136/4885MC4R 84/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.